Hasta la próxima

Auto reproducción

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat

10 vistas • 07/08/23
Compartir
Empotrar
administrator
administrator
Suscriptores
0

UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat

Mostrar más
0 Comentarios sort Ordenar por
Comentarios de Facebook

Hasta la próxima

Auto reproducción